Helping midlife adults change health behaviors to reduce Alzheimer's risk
Development of a Personalized Intervention to Motivate Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease
This study is trying to help midlife adults change their eating, exercise, and mental habits to lower their chances of getting Alzheimer's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 45 Years to 69 Years |
| Sex | All |
| Sponsor | Rhode Island Hospital Academic / other |
| Locations | 1 site (Providence, Rhode Island) |
| Trial ID | NCT05599425 on ClinicalTrials.gov |
What this trial studies
This project focuses on modifying health behaviors such as physical activity, diet, and mental engagement to lower the risk of Alzheimer's disease in midlife adults. It aims to develop an intervention that educates participants about Alzheimer's risk factors and addresses personal health beliefs that hinder long-term lifestyle changes. The intervention includes enhanced and basic healthy living education to support participants in sustaining these changes over time.
Who should consider this trial
Good fit: Ideal candidates are adults aged 45-69 with normal cognition and at least two risk factors for Alzheimer's disease.
Not a fit: Patients with serious mental illnesses or current substance use disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly reduce the risk of developing Alzheimer's disease in at-risk individuals.
How similar studies have performed: Other studies have shown promise in using health behavior modifications to reduce Alzheimer's risk, indicating that this approach is both relevant and potentially effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 45-69 years * normal cognition (Minnesota Cognitive Acuity Scale \> 52) * English language fluency * at least two of the following: i) BMI \> 24.9; ii) systolic blood pressure \> 125 mmHg; iii) LDL cholesterol \> 115 mg/dL; iv) HbA1C \> 6.0%; v) at least one APOE ε4 allele; vi) first-degree relative with AD. Exclusion Criteria: * history of serious mental illness (i.e., schizophrenia, bipolar disorder) * history of neurologic or neurodevelopmental disorder * current alcohol or drug use disorder based on self-report * current enrollment in an AD prevention clinical trial.
Where this trial is running
Providence, Rhode Island
- Rhode Island Hospital — Providence, Rhode Island, United States (Recruiting)
Study contacts
- Study coordinator: Laura Korthauer, PhD
- Email: laura_korthauer@brown.edu
- Phone: 4014444500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.